We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| TFF Pharmaceuticals Inc | NASDAQ:TFFP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.28 | -11.34% | 2.19 | 1.96 | 14.38 | 2.67 | 2.01 | 2.67 | 85,519 | 05:00:02 |
From May 2019 to May 2024
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the 2021 BIO CEO & Investor Digital Conference, being held virtually on February 16-18, 2021.
Glenn Mattes, President & CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at the conference. The recording will be available on-demand to registered conference attendees via the BIO conference portal for 30 days and can be accessed in the Investor Relations section of the TFF Pharmaceuticals website.
The Company will also participate in investor and partnering meetings with conference attendees during the event.
About TFF Pharmaceuticals’ Thin Film Freezing technology platform TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005267/en/
Company Contacts: Glenn Mattes President and CEO TFF Pharmaceuticals, Inc. gmattes@tffpharma.com 737-802-1973 Kirk Coleman Chief Financial Officer TFF Pharmaceuticals, Inc. kcoleman@tffpharma.com 817-989-6358 Investor Relations and Media Contact: Paul Sagan LaVoieHealthScience psagan@lavoiehealthscience.com 617-953-4779
1 Year TFF Pharmaceuticals Chart |
1 Month TFF Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
